Table 1.
Patient and treatment characteristics.
| Study population | |
|---|---|
| N = 167 (100%) | |
| Gender | |
| Female | 77 (46.1) |
| Male | 90 (53.9) |
| Age (years)a | |
| Median (interquartile range) | 67.1 (62.7–72.7) |
| Regimen 1st line palliative chemotherapy | |
| Gemcitabine | 70 (41.9) |
| Gem/NabP | 46 (27.5) |
| Gem/Cap | 14 (8.4) |
| FOLFIRINOX | 14 (8.4) |
| 5-FU/FA/Ox | 9 (5.4) |
| Capecitabine | 8 (4.8) |
| Cap/Ox | 3 (1.8) |
| Othersb | 3 (1.8) |
| Time to treatment failure under 1st line | 166 |
| treatment (TTF1) (months) no | |
| Median (interquartile range) | 3.65 (2.3–7.2) |
| ECOG PSa, no | 122 |
| 0 | 25 (20.5) |
| 1 | 70 (57.4) |
| 2 | 26 (21.3) |
| 3 | 1 (0.8) |
| Extent of tumor spreada | |
| Locally advanced | 22 (13.2) |
| Metastatic disease | 145 (86.8) |
| CA 19-9 (kU/L)a, no | 103 |
| Median (interquartile range) | 1,550 (200–18,082) |
| Albumin (g/L)a, no | 141 |
| Median (interquartile range) | 35.0 (32.5–37.0) |
| 2nd line palliative chemotherapy | |
| Monotherapy | 68 (40.7) |
| Combination therapy | 99 (59.3) |
| Regimen 2nd line chemotherapy | |
| 5-FU/FA/Ox | 48 (28.7) |
| Capecitabine | 37 (22.2) |
| Cap/Ox | 18 (10.8) |
| Gemcitabine | 16 (9.6) |
| 5-FU/FA | 14 (8.4) |
| 5-FU/FA/Iri | 11 (6.6) |
| Gem/NabP | 10 (6.0) |
| Gem/Cap | 5 (3.0) |
| FOLFIRINOX | 4 (2.4) |
| Othersc | 4 (2.4) |
a
at start of 2nd line chemotherapy.
b
5-FU/FA, Gemcitabine/Oxaliplatin, Gemcitabine/AMG479.
c
Gemcitabine/Oxaliplatin, Erlotinib, Dabrafenib/Trametinib.
Gem/NabP, gemcitabine plus nab-paclitaxel; Gem/Cap, gemcitabine plus capecitabine; FOLFIRINOX, 5-flourouracil, folinic acid, irinotecan, and oxaliplatin; 5-FU/FA/Ox, 5-flourouracil, folinic acid, and oxaliplatin; Cap/Ox, capecitabine plus oxaliplatin; ECOG PS, Eastern Cooperative Oncology Group performance status; 5-FU/FA, 5-flourouracil plus folinic acid; 5-FU/FA/Iri, 5-flourouracil, folinic acid, and irinotecan.